Close menu




January 24th, 2022 | 11:09 CET

BioNTech, Cardiol Therapeutics, Netflix - The return to normality

  • Biotechnology
Photo credits: pixabay.com

The outbreak of the Corona pandemic triggered gold-rush sentiment among many companies. In addition to vaccine manufacturers such as BioNTech and Moderna, stocks whose technology supported the mandated measures also multiplied. Whether shopping, school, work or even sports, one could suddenly do everything simply in front of a screen. However, after the restrictions and limitations, society longs for normal life to return. These developments can be seen clearly in the share charts and the most recently presented figures.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , NETFLIX INC. DL-_001 | US64110L1061

Table of contents:


    Vaccine producers as winners

    Since the approval of the vaccine Comirnaty, formerly known as BNT162b2, in December 2020, the bull market of BioNTech, founded in 2008, got rolling. In the process, the Mainz-based Company built on years of research into developing and producing technologies and drugs for individualized cancer immunotherapies based on mRNA. The mRNA contains the "blueprint" for a protein on the surface of the SARS-CoV-2 coronavirus. Through vaccination, this blueprint enters the body's cells via tiny nanoparticles.

    Side effects can often include pain at the injection site, fever, headache, and muscle or joint pain. According to experts, inflammation of the heart muscle or pericardium due to mRNA vaccination is extremely rare, but it does occur time and again. The first cases were reported in Israel in the spring of 2021. Studies in the United States established a link between Corona vaccination and myocarditis or pericarditis.

    Successful against myocarditis

    The treatment of myocarditis is among the future therapies of Cardiol Therapeutics. Because myocarditis is also one of the side effects of current vaccination campaigns, the scientific community is likely to be eagerly awaiting the completion of clinical trials. What is additional is that the Oakville, Canada-based Company relies on an oral cannabidiol formulation pharmaceutically manufactured according to cGMP for its lead product, CardiolRx, which is currently being studied in a Phase II/III outcomes trial.

    Recently, researchers at Oregon State University released a research paper titled "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants," showing that cannabinoids may block cellular entry of SARS-CoV-2 and the emerging variants.

    The objective of Cardiol's currently ongoing Lancer study is to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapeutic to reduce mortality and major cardiovascular events in hospitalized COVID-19 patients with pre-existing cardiovascular disease or risk factors for CVD and to evaluate the impact of CardiolRx on key markers of inflammatory heart disease. To read a detailed report on the Company, visit researchanalyst.com/en/report/cardiol-therapeutics-shares-with-blockbuster-potential.

    In addition to CardiolRX, which is believed to have blockbuster potential, the biotech company boasts approval of its investigational IND for an international Phase II study from the FDA to evaluate the anti-inflammatory and anti-fibrotic properties of CardiolRx in acute myocarditis, a leading cause of sudden cardiac death in people under the age of 35. With a successfully completed capital increase of USD 50 million, Cardiol Therapeutics is well funded to push ahead with further clinical trials.

    Currently, the market capitalization of the share, which is traded not only on the Toronto Stock Exchange but also on the Nasdaq and in Frankfurt, is EUR 98.07 million. If one compares the Company with similar stocks from the industry, whose market capitalization is many times higher, this gap is likely to close quickly if the study results are successful. Cardiol is currently quoted at USD 1.82. The previous high was USD 10.

    Various analyst firms have recently expressed optimism for the further development of the shares. In addition to Canaccord Genuity, which issued a price target of USD 8.00, analyst firm Leede Jones Gable even sees CAD 12.50 for the buy candidate. On average, the forecasts of the experts are at CAD 11.00.

    On February 17, 2022, Cardiol will present at the "International Investment Forum - IIF" and provide investors with further insight. Interested investors can register free of charge at www.ii-forum.com.

    Life with Corona

    For now, Netflix investors have had enough. It could well be that instead of pursuing the abundant streaming offer, society is once again devoting itself more to life outdoors. At least, that is how one could interpret Netflix's figures. Despite "Squid Game" & Co., the US company missed its growth target for the expired fiscal year by a wide margin.

    In the last quarter of 2021, the global number of subscribers increased by 8.3 million to a total of just under 222 million. As a result, the Company's target of 8.5 million new customers was narrowly missed. Revenue increased by 16% YOY to USD 7.7 billion, and profit grew by just under 12% to USD 607 million.

    For the current quarter, Netflix expects only 2.5 million new customers. In addition, operating as well as net income is expected to decline. The stock plunged with a loss of more than 21% to USD 397.50. The next support zone is at USD 387.


    Voices are piling up that after the wave of the Omicron variant, normal life could return without major restrictions, which makes Corona winners such as BioNTech and Netflix correct sharply. In contrast, Cardiol's cannabidiol-based products combat heart muscle inflammation, the leading cause of sudden cardiac death, and have significant upside potential if study results continue to be positive.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.

    Read